Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Published March 14, 2019
Citation Information: JCI Insight. 2019;4(8):e127882. https://doi.org/10.1172/jci.insight.127882.
View: Text | PDF
Research Article Immunology

Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes

  • Text
  • PDF
Abstract

MHC I–restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8+ T cells as probes. Here, using bioinformatics tools, we identify 4 additional epitopes in OVA in addition to a cryptic epitope. Each additional epitope is presented in vivo, as deduced from the lack of CD8+ T cell response to it in OVA-transgenic mice. In addition, CD8 responses to the previously known epitopes and those identified in this study are examined in C57BL/6J mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope, including SIINFEKL, are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti–CTLA-4 antibody, which depletes tumor-infiltrating regulatory T cells, are CD8 responses to SIINFEKL and the epitope EKYNLTSVL identified in this study detected. Finally, all epitopes fail to treat mice with preexisting tumors. These observations force an important reconsideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.

Authors

Sukrut Hemant Karandikar, John Sidney, Alessandro Sette, Mark Joseph Selby, Alan Jerry Korman, Pramod Kumar Srivastava

×

Figure 3

Epitopes of OVA induce tolerance when expressed endogenously.

Options: View larger image (or click on image) Download as PowerPoint
Epitopes of OVA induce tolerance when expressed endogenously.
(A) Peptid...
(A) Peptide 36–43 (SALAMVYL) is present in 2 proteins expressed by mice. Peptide 36–43 was aligned against all nonredundant mouse (taxid:10090) protein sequences. Thirty-nine–amino acid regions of OVA and 2 mouse proteins containing peptide 36–43 are shown. Numbers flanking the sequences indicate the position (from the N-terminus) of the first and the last depicted amino acid. (B) Act-mOVA mice are tolerized toward all epitopes of OVA. C57BL/6J mice (red) or Act-mOVA (blue) were immunized with OVA and CD8+ T cell responses against the indicated epitopes were tested (n = 3; experiment performed 2 times; unpaired t test). (C) Act-mOVA mice are not tolerized toward peptide 208–216. Wild-type C57BL/6J (left panel) or Act-mOVA (right panel) mice were immunized with peptides 27–35, 55–62, 208–216, and 257–264. CD8 responses were tested 7 days after immunizations (n = 3 for both panels; experiment performed 2 times; unpaired t test). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts